Table 1.

Summary of the published cases reporting KE

Study	Organism identified	Cause	Presentation features	Pre-treatment VA	BCVA at last follow-up	Treatment	Presumed anatomic success*
Duan et al. [2]	K. kristinae	Trauma	N/A	N/A	N/A	N/A	N/A
Dave et al. [4]	K. kristinae	Trauma	Hypopyon		20/60	Intravitreal vancomycin and ceftazidime	Yes
	K. kristinae	Trauma	Hypopyon	LPa	20/60	Intravitreal vancomycin and ceftazidime	Yes
	K. kristinae	Trauma	Hypopyon, corneal edema	LP	HM	PPVb/PPLc/intravitreal vancomycin and ceftazidime	No
	K. varions	Keratitis	Corneal edema	HMd	HM	Intravitreal vancomycin and ceftazidime, adhesive tissue application	Yes
	K. rosea	Trauma	Cataract	20/400	20/2,400	Intravitreal vancomycin and ceftazidime	Yes
	K. rosea	Trauma	Hypopyon	LP	HM	PPV/PPL/intravitreal vancomycin and ceftazidime	No
	K. rosea	Endogenous	Hypopyon, corneal edema	LP	HM	PPV/PPL/intravitreal vancomycin and ceftazidime	Yes
	K. rosea	Postoperative	Corneal edema, inflammation	CFe	20/80	PPV, intravitreal vancomycin, and ceftazidime	Yes
Alles et al. [5]	K. kristinae	Post-intravitreal injection	Hypopyon, vitritis	N/A	N/A	PPV/intravitreal vancomycin, ceftazidime, and moxifloxacin, then PPV	Yes
Present study	K. kristinae	Trauma	Fibrin, vitritis inflammation	LP	20/50	Intravitreal vancomycin and ceftazidime, then PPV	Yes

^aLP, light perception.

^bPPV, pars plana vitrectomy.

^cPPL, pars plana lensectomy.

^dHM, hand motions.

^eCF, counting fingers.

^*Anatomic success was defined preserved globe, absence of hypotony, retinal attachment, and absence of active inflammation.